SI-BONE, Inc. (NASDAQ:SIBN) Shares Purchased by Champlain Investment Partners LLC

Champlain Investment Partners LLC boosted its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 14.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,800,073 shares of the company’s stock after purchasing an additional 358,821 shares during the quarter. Champlain Investment Partners LLC owned approximately 0.07% of SI-BONE worth $39,145,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Canada Pension Plan Investment Board purchased a new stake in shares of SI-BONE during the second quarter worth approximately $61,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of SI-BONE by 24.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after purchasing an additional 2,108 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of SI-BONE by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after purchasing an additional 903 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of SI-BONE during the 2nd quarter worth $151,000. Finally, Assenagon Asset Management S.A. acquired a new position in shares of SI-BONE during the second quarter worth $152,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Laura Francis sold 10,048 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $12.58, for a total value of $126,403.84. Following the transaction, the chief executive officer now owns 482,875 shares in the company, valued at $6,074,567.50. The trade was a 2.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Anthony J. Recupero sold 3,937 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $12.60, for a total value of $49,606.20. Following the sale, the insider now directly owns 228,554 shares of the company’s stock, valued at approximately $2,879,780.40. This represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,093 shares of company stock valued at $299,558 over the last quarter. Company insiders own 3.90% of the company’s stock.

SI-BONE Stock Up 2.2 %

SI-BONE stock opened at $12.56 on Friday. The company has a market capitalization of $526.77 million, a P/E ratio of -13.65 and a beta of 1.22. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $21.70. The stock has a 50-day simple moving average of $13.72 and a 200-day simple moving average of $14.21.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SIBN. Morgan Stanley decreased their price target on SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of SI-BONE in a research note on Wednesday. Finally, Truist Financial upped their price target on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SI-BONE currently has an average rating of “Buy” and an average price target of $23.00.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.